HUE030733T2 - Az epidermális növekedési faktor receptorhoz specifikusan kötõdõ ellenanyagok - Google Patents

Az epidermális növekedési faktor receptorhoz specifikusan kötõdõ ellenanyagok Download PDF

Info

Publication number
HUE030733T2
HUE030733T2 HUE09850100A HUE09850100A HUE030733T2 HU E030733 T2 HUE030733 T2 HU E030733T2 HU E09850100 A HUE09850100 A HU E09850100A HU E09850100 A HUE09850100 A HU E09850100A HU E030733 T2 HUE030733 T2 HU E030733T2
Authority
HU
Hungary
Prior art keywords
seq
antibody
cdr
variable region
amino acid
Prior art date
Application number
HUE09850100A
Other languages
English (en)
Inventor
Se-Ho Kim
Ki Hwan Chang
Kwang-Won Hong
Yong-Won Shin
Min-Soo Kim
Hae-Won Lee
Yong Nam Shin
Kyung Hwan Ryoo
Dong Hyuck Seo
Jong-Hwa Won
Min-Kyu Hur
Original Assignee
Green Cross Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Green Cross Corp filed Critical Green Cross Corp
Publication of HUE030733T2 publication Critical patent/HUE030733T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (6)

  1. Szabadalmi igénypontok
    1 - Az epsdsrsnália növekedési Mm reeeptörhox CBOFIQ -speetfsknsa» kótódö ellenanyag, amely tartalmaz: a> a SBQ ID NO; 1, 2 és 3 szerinti amlnnsav-azekveneiájó komplementaritást meghatározó régió (CDR) s-i, CDR 2-t év CDR 3-t tartalmazd nehéziám; variábilis régiót; b) a SBQ 10 NO: Q ? és 6 szerinti amí:ttöS8v-szgkveariá)é CDR 1-1, CDR 24 és CDR 3-t tartalmazó kómsyüiánc variábilis régiót; cl oehéziát-e konstans régiét; és d) könnydiánc konstans régiót.
  2. 2. Az i, igénypont szerűid ellenanyag, amely tartalmaz: &) a SEQ 1D NO: 2 szériák ammoutv-szekvenciájó nehéalánc variábilis régiói; b) a SBQ 1D MO: % szerimi aminesav-szekveneiájó MnnySláse variábilis régiót; c) nehézláoc konstans-régiót; és d) kőnnyőlánc konstans régiói.
  3. 3. DNS, amely SBQ ID NO: 1, 2 és 3 szerinti aminesev-szekveoeiájö CDR í~t, CDR 24 és CDR 34 tartalmazó ellenanyag nehézláne variábilis régiót: kódol; és DNS. amely SEQ ÍD NO: 4, 5 és ó szerinti anrinomv-szekveneiájó CDR i~t, CDR 2-t és CDR 34 tartalmazó ellenanyag könnyüláne variábilis régiót kódöl; ahol az ellenanyag specifikusan kötódlk az epidemtális növekedési táktor receptorhoz. (BCFR). 4. A 3, igénypont szerinti DNS, amely a SBQ ID NO: S szerinti aminos&v -szék vétse iát kódoló SBQ ID NO: 11 szerinti szekvenciáié gmmukleolidot, a SBQ ID NO 2 szériáit armoosav'szekvenciát kódoló SBQ ID NO; 12 szerinti szekvenciáin jxdmukleottdot, és & SBQ 1D NO; 2 szerinti amíoosav-szekvonciái kódoló SBQ 113 NO: 13 szerinti szekvenciája göRottklsolidot tartalmaz; és amely a SEQ ID NO: 4 szerinti amiuosav-saeskvcnctát kódosé SEQ ID NO 15 szenmi szekvenciája pnlinuklentidnt; a SBQ) 1D NO: 5 szerinti amiaosav-szekvenciái: kódold SEQ ID NO- 16 szerinti szekvenciája policmkleotidot; és a SBQ ÍD NO: 6 szerinti ammesev-szekvendát kódoló SBQ ID NO: I? szerinti szekvenciáid poiiookleetláot tartehsaz. > Λ 5 igénypont szerinti DNS, amely a SBQ 10 NO: ? szerinti stnrinösav'-szekvenelájá ellenanyag nenéziáne va» mb illa régiót kódol; és sj.sn.dy a SEQ 1D NO 8 szerinti ammesav-sækvmtcMfd ellenanyag könnytilénc variábilis régiót kódol.
  4. 6, Az 5. igénypont szerinti DNS, amely a SBQ 1D NO; ? szerinti aminosav-szefevenciát kódoló SEQ ID NO: 14 szerinti nnkieeéid-szekvenciájó potinukícotldoi tartat máz: és amely a SEQ ID NO: 8 szerinti amiaosav-szskvetseiát kódoló SEQ ÍD NO: IS szerinti nakieotid-sxekvends^á poHnukteoíidot tartalmaz, ?. Expresszié* vektor az t^ldermáiis növekedést faktor meepkahoz (EGER) speciSkossn kólód» ellenanyag nsbórianc variábilis régiójának ás könnyéiért« variábilis .régiójának exptesszálásárs, amely 3, igénypont szerinti DNS4 tartalmaz. 8. A ?, igénypont szerinti expresszié* vektor, -amely az ERMIeevy-pRClS, amelynek térképét -az 3, ábra mutatja; és amely az ER2-Light-pK€12. amelynek a térképét a 6. ábra rnotatja.
  5. 9. Allan sejtvonai, amely a 7, igénypont szerinti expresszié* vektorral vas; trattssíormálvis.
  6. 10. Készítmény rák kezelésére* amely 1. igénypont szerinti ellenanyag tartalmaz,
HUE09850100A 2009-09-29 2009-11-02 Az epidermális növekedési faktor receptorhoz specifikusan kötõdõ ellenanyagok HUE030733T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020090092401A KR101108642B1 (ko) 2009-09-29 2009-09-29 표피 성장 인자 수용체에 특이적으로 결합하는 항체

Publications (1)

Publication Number Publication Date
HUE030733T2 true HUE030733T2 (hu) 2017-05-29

Family

ID=43826456

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE09850100A HUE030733T2 (hu) 2009-09-29 2009-11-02 Az epidermális növekedési faktor receptorhoz specifikusan kötõdõ ellenanyagok

Country Status (19)

Country Link
US (1) US8748175B2 (hu)
EP (1) EP2483309B1 (hu)
JP (1) JP5729839B2 (hu)
KR (1) KR101108642B1 (hu)
CN (1) CN102574919B (hu)
BR (1) BR112012007082B1 (hu)
CA (1) CA2774427C (hu)
DK (1) DK2483309T3 (hu)
ES (1) ES2592883T3 (hu)
HR (1) HRP20161459T1 (hu)
HU (1) HUE030733T2 (hu)
LT (1) LT2483309T (hu)
MX (1) MX2012003662A (hu)
MY (1) MY163502A (hu)
PL (1) PL2483309T3 (hu)
PT (1) PT2483309T (hu)
RU (1) RU2518239C2 (hu)
SI (1) SI2483309T1 (hu)
WO (1) WO2011040668A1 (hu)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2694679T3 (es) * 2012-03-27 2018-12-26 Green Cross Corporation Epitopos de antígeno de superficie receptor de factor de crecimiento epidérmico y uso de los mismos
JP6324381B2 (ja) 2012-07-31 2018-05-16 クラウン バイオサイエンス インコーポレイテッド（タイカン） 抗ｅｇｆｒ薬物による処置のための非小細胞肺癌患者を同定するための組織学的マーカー
CN102993305B (zh) * 2012-11-16 2015-05-13 上海赛伦生物技术有限公司 人源抗人表皮生长因子受体抗体及其编码基因与应用
CN104341505A (zh) * 2013-07-29 2015-02-11 西藏海思科药业集团股份有限公司 对蒙古人种和高加索人种低免疫原性的、抗egfr的人鼠嵌合抗体
KR102089591B1 (ko) * 2013-07-29 2020-03-18 삼성전자주식회사 항 EGFR scFv 단편 및 이를 포함하는 항 c-Met/항 EGFR 이중 특이 항체
KR101591823B1 (ko) 2013-12-27 2016-02-04 재단법인 목암생명공학연구소 증가된 유전자 발현능을 갖는 발현벡터
KR101776879B1 (ko) * 2015-01-19 2017-09-08 주식회사 녹십자 항-egfr 항체를 포함하는 약학 제제
KR101782632B1 (ko) 2016-01-11 2017-09-27 주식회사 녹십자 표피 성장 인자 수용체에 특이적으로 결합하는 항체를 유효성분으로 포함하는 암 치료용 조성물
SI3449939T1 (sl) * 2016-04-27 2022-06-30 Green Cross Corporation Farmacevtski sestavek za zaviranje metastaz pri raku, ki kot učinkovino obsega protitelo, ki se specifično veže na receptor za epidermalni rastni faktor
KR101966362B1 (ko) * 2017-10-20 2019-04-05 주식회사 녹십자 항-msln 항체 및 이를 포함하는 암 치료용 약학적 조성물
JP7049389B2 (ja) * 2020-05-01 2022-04-06 グリーン・クロス・コーポレイション 上皮成長因子受容体に特異的に結合する抗体を有効成分として含む、癌の転移を抑制するための医薬組成物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0699237T3 (da) * 1994-03-17 2003-05-26 Merck Patent Gmbh Anti-EGFR enkeltkæde FV'er og anti-EGFR-antistoffer.
CA2616914C (en) 1996-12-03 2012-05-29 Abgenix, Inc. Egfr-binding antibody
US20020173629A1 (en) * 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
AU2002211658A1 (en) 2000-10-13 2002-04-22 Uab Research Foundation Human anti-epidermal growth factor receptor single-chain antibodies
CA2450285C (en) 2001-06-13 2016-08-02 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (egfr)
EP1735348B1 (en) * 2004-03-19 2012-06-20 Imclone LLC Human anti-epidermal growth factor receptor antibody
KR100523732B1 (ko) 2004-08-27 2005-10-26 주식회사 녹십자홀딩스 Ｂ형 간염 바이러스의 표면 항원에 대한 인간항체의가변영역을 삽입할 수 있는 항체발현 플라스미드
KR100635370B1 (ko) 2005-03-04 2006-10-17 주식회사 녹십자홀딩스 ＳｃＦｖ 형태의 항체 라이브러리를 제작하기 위한 항체 ＳｃＦｖ 발현벡터
KR100624011B1 (ko) 2005-04-20 2006-09-19 주식회사 녹십자 항-파상풍 단일클론항체 및 이를 생산하는 하이브리도마세포주
KR100680141B1 (ko) 2005-04-20 2007-02-07 주식회사 녹십자 항-ｅｇｆ 수용체 단일클론항체 및 이를 생산하는하이브리도마 세포주
CN101432015A (zh) * 2006-02-15 2009-05-13 英克隆系统公司 功能性抗体
EP1829895A1 (en) * 2006-03-03 2007-09-05 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies
US9023356B2 (en) * 2007-03-15 2015-05-05 Ludwig Institute For Cancer Research Ltd Treatment method using EGFR antibodies and SRC inhibitors and related formulations
EP2190878A1 (en) * 2007-09-06 2010-06-02 Genmab A/S Novel methods and antibodies for treating cancer

Also Published As

Publication number Publication date
CN102574919A (zh) 2012-07-11
SI2483309T1 (sl) 2016-10-28
ES2592883T3 (es) 2016-12-02
MY163502A (en) 2017-09-15
WO2011040668A1 (en) 2011-04-07
KR20110034914A (ko) 2011-04-06
BR112012007082B1 (pt) 2022-07-12
US20120231021A1 (en) 2012-09-13
JP5729839B2 (ja) 2015-06-03
RU2012117753A (ru) 2013-11-10
BR112012007082A2 (pt) 2017-06-27
PT2483309T (pt) 2016-09-02
CA2774427A1 (en) 2011-04-07
HRP20161459T1 (hr) 2016-12-16
KR101108642B1 (ko) 2012-02-09
JP2013505736A (ja) 2013-02-21
EP2483309B1 (en) 2016-08-17
PL2483309T3 (pl) 2017-02-28
CA2774427C (en) 2015-03-31
MX2012003662A (es) 2012-05-08
DK2483309T3 (en) 2016-11-28
RU2518239C2 (ru) 2014-06-10
CN102574919B (zh) 2014-12-10
EP2483309A1 (en) 2012-08-08
LT2483309T (lt) 2016-11-25
EP2483309A4 (en) 2013-07-17
US8748175B2 (en) 2014-06-10

Similar Documents

Publication Publication Date Title
DK2483309T3 (en) Antibodies that bind specifically to the epidermal growth factor receptor
JP5690356B2 (ja) 完全ヒト型抗ｈｅｒ２モノクローナル抗体、その調製方法および用途
CA2478169C (en) Human antibodies specific to kdr and uses thereof
CN101443361B (zh) 与受体酪氨酸激酶alk的胞外域结合的抗体
CN113603783B (zh) 蛋白酶可切割的双特异性抗体及其用途
WO2008004834A1 (en) Humanized monoclonal antibody highly binding to epidermal growth factor receptor, egf receptor
JP2003501348A (ja) ＴＧＦβ１に対する特異的抗体および抗体フラグメント
KR20040023590A (ko) 혈관 내피 성장 인자 수용체 길항제를 이용한 종양 성장의병용 억제 방법
EP2093236A1 (en) Recombinant antibodies against vascular endothelial growth factor (vegf)
CN113754775A (zh) 一种抗pd-l1和her2的双特异性抗体
WO2021083248A1 (zh) 抗tspan8单克隆抗体及其用途
CN112830968B (zh) 抗VEGF单域抗体及其人源化、单域抗体和IgG1-Fc构建的融合蛋白和应用
US9657096B2 (en) Human domain antibodies against components of the human insulin-like growth factor (IGF) system
CN116554324B (zh) 一种特异性识别4-1bb的抗体、其制备方法及其用途
CN111417654B (zh) 具有增加的对于表皮生长因子受体的亲和力的抗体及其衍生片段
AU2014256364B2 (en) Human domain antibodies against components of the human insulin-like growth factor (IGF) system